ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

COVID-19’s impact on the vagus nerve, inflammatory reflex & long COVID: Feinstein Institutes & Karolinska Institutet study outlines potential therapies

A new study published in the Journal of Internal Medicine details the connection between SARS-CoV-2, the vagus nerve and hyperinflammation

A hallmark of fatal SARS-CoV-2 infection (COVID-19) is cytokine storm – an increase of inflammatory proteins within the body – that can lead to respiratory distress and organ failure. A new study published today in the Journal of Internal Medicine (JIM) by researchers at The Feinstein Institutes for Medical Research and the Karolinska Institutet discuss the relationship between COVID-19, the vagus nerve, the body’s inflammatory reflex and the therapeutic potentials to treat the disease and long-COVID.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231129335345/en/

Dr. Kevin J. Tracey co-authored a new paper on the relationship between SARS-CoV-2 and the vagus nerve. (Credit: Feinstein Institutes)

Dr. Kevin J. Tracey co-authored a new paper on the relationship between SARS-CoV-2 and the vagus nerve. (Credit: Feinstein Institutes)

The paper, titled “Vagus Nerve SARS-CoV-2 Infection and Inflammatory Reflex Dysfunction: Is there a causal Relationship?” written by Kevin J. Tracey, MD, president and CEO of the Feinstein Institutes and Ulf Andersson, PhD, professor emeritus in the Department of Women’s and Children’s Health at the Karolinska Institutet, looks at the current research and evidence that impairment of the body’s vagus nerve inflammatory reflex may contribute to the overproduction of cytokines and hyperinflammatory progression of COVID-19.

“The discovery that SARS-CoV-2 can infect the vagus nerve introduces new questions for researchers studying both COVID-19 and post-COVID-19 syndrome,” said Dr. Tracey, who is the Karches Family Distinguished Chair in Medical Research. “This paper raises foundational questions for future basic and clinical investigations, aiming to study innovative therapies for addressing the disease and its long-term complications.”

Originating in the brain and extending to the body’s organs, the vagus nerve helps communicate and maintain how the body functions, including heart rate, breathing and immune response, and the release of inflammatory proteins like high mobility group box 1 protein (HMGB1). This neural communication pathway, which is meant to sustain the body’s natural state or homeostasis, was previously discovered by Dr. Tracey, which he termed the “inflammatory reflex.” If the vagus nerve and the inflammatory reflex are compromised, too much or too little inflammatory proteins are released in the body, causing diseases like rheumatoid arthritis, Crohn’s disease or, as evidence shows, respiratory impairment and hyperinflammation in people with COVID-19.

Drs. Tracey and Andersson cite evidence in the current paper that shows SARS-CoV-2 infection within the vagus nerve at the acute stage of the disease may hamper its inflammatory reflex and proper functioning. They outline existing research looking at the interplay between two molecules, HMGB1 and acetylcholine, and the role of regulating inflammation. They also discussed potential therapies, particularly to reduce the progression of COVID-19 in infected patients as well as long COVID-19 treatment options. Famotidine, a histamine 2 receptor-antagonist, has been shown to attenuate the clinical course of COVID-19 and may be an inexpensive and safe way to treat the disease. However, future study is needed. Additionally, the role of electronic vagus nerve stimulation (VNS) was discussed in the paper. VNS can be performed using surgically implanted cervical vagus nerve electrodes or non-invasive transcutaneous electrical vagal stimulation and help “reset” the vagus nerve to regulate better and prevent the increase of inflammatory proteins.

“Studying the connection between COVID-19 and the vagus nerve is an important research avenue that needs further study,” said Dr. Andersson. “We need to understand better the underlying molecular mechanisms of the disease to develop new clinical treatments that can aid individuals infected with SARS-CoV-2 and in their recovery.”

Recent data demonstrates that the vagus nerve is infected and inflamed during severe COVID-19. That understanding raises many questions and potential pathways of research to develop new ways of preventing potentially fatal disease progression and long-lasting effects of COVID-19.

The Feinstein Institutes for Medical Research is the global scientific home of bioelectronic medicine, which combines molecular medicine, neuroscience, and biomedical engineering. At the Feinstein Institutes, medical researchers use modern technology to develop new device-based therapies to treat disease and injury.

Built on years of research in molecular mechanisms of disease and the link between the nervous and immune systems, our researchers discover neural targets that can be activated or inhibited with neuromodulation devices, like vagus nerve implants, to control the body’s immune response and inflammation. If inflammation is successfully controlled, diseases – such as arthritis, pulmonary hypertension, Crohn’s disease, inflammatory bowel diseases, diabetes, cancer and autoimmune diseases – can be treated more effectively.

Beyond inflammation, using novel brain-computer interfaces, Feinstein Institutes researchers developed techniques to bypass injuries of the nervous system so that people living with paralysis can regain sensation and use their limbs. By producing bioelectronic medicine knowledge, disease and injury, could one day be treated with our own nerves without costly and potentially harmful pharmaceuticals.

About the Feinstein Institutes 

The Feinstein Institutes for Medical Research is the home of the research institutes of Northwell Health, the largest health care provider and private employer in New York State. Encompassing 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health system science, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine. For more information about how we produce knowledge to cure disease, visit http://feinstein.northwell.edu and follow us on LinkedIn.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  234.42
+0.54 (0.23%)
AAPL  286.19
+3.09 (1.09%)
AMD  215.24
-4.52 (-2.06%)
BAC  53.19
-0.05 (-0.09%)
GOOG  316.02
+0.90 (0.29%)
META  647.10
+6.23 (0.97%)
MSFT  490.00
+3.26 (0.67%)
NVDA  181.46
+1.54 (0.86%)
ORCL  201.10
+0.16 (0.08%)
TSLA  429.24
-0.90 (-0.21%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.